Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings
REGNRegeneron(REGN) Seeking Alpha·2024-07-12 05:41

serggn/iStock via Getty Images Investment Overview: Regeneron Recap Illustrates High Valuation, Justified By High Potential I last covered the Watertown, Massachusetts "Big Pharma" concern Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a note for Seeking Alpha in January, titled "Why I Expect Regeneron To Keep Delivering For Investors In 2024 (Upgrade)." At that time, Regeneron shares were worth $895 per share. While making the point that by some metrics - price-to-sales, price-to-earnings, comparisons ag ...